June 15, 2011 (Montreal, Quebec City) — Injection of a diagnostic echo-contrast agent in patients undergoing right heart catheterization did not alter baseline pulmonary pressures from baseline levels ...
PRINCETON, NJ ─ November 18, 2013 ─ GE Healthcare announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to allow the company to manufacture Optison™ ...
Optison is an ultrasound contrast agent available in a ready-to-use formulation, providing the benefits of fast preparation time, ease of use, portability, and flexible dosing. 2 The recommended dose ...
GE Healthcare today announced important changes to the U.S. product label for Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a contrast agent that may improve the ...
GE Healthcare Files Supplemental New Drug Application for Its Own Manufacturing of Optison™ (Perflut
GE Healthcare Files Supplemental New Drug Application for Its Own Manufacturing of Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP) Upon Approval, GE Healthcare's Oslo ...
GE Healthcare Medical Diagnostics announced the market reintroduction of Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a diagnostic ultrasound contrast agent for use in ...
Today, GE Healthcare Medical Diagnostics announced results of a study that evaluated the cardiopulmonary safety of Optison (Perflutren Protein-Type A Microspheres Injectable Suspension, USP), a ...
GE Healthcare announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to allow the company to manufacture Optison™ (Perflutren Protein-Type A Microspheres ...
Although contrast agents have an essential role in non-invasive imaging techniques, potential side effects limit their use. For example, both low- and iso-osmolar iodinated contrast media used in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results